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Abstract
Background: Studies in western populations have shown a positive association between depression and cardiovascular
disease (CVD) and all-cause mortality. The association with depressive symptoms seems to be graded, rather than
limited to the presence versus the absence of depression. Evidence from populations with potentially different patterns
of confounders helps to address the consistency of these findings. The objective of the study was to investigate the
association between depressive symptoms and all-cause and CVD mortality in populations of Central and Eastern
Europe.
Study design: This was a prospective cohort study.
Methods: A total of 24,542 participants aged 45–69 years, randomly selected from populations of Novosibirsk (Russia),
Krakow (Poland) and six Czech towns, were included. Depressive symptoms, assessed by the 20-item Center for
Epidemiologic Studies Depression (CES-D) scale, were used as both continuous and categorical variables. Data on
deaths were obtained from local or national death registers. Associations between depression and mortality were
assessed using Cox proportional hazards models.
Results: Over a median of 7 years, 2091 deaths from all causes and 850 CVD deaths occurred in the cohorts. There was
a graded association between CES-D score and mortality; the hazard ratio (HR) of CVD mortality for a 1 SD increase in
CES-D was 1.20 (95% confidence interval (CI): 1.16–1.24) in men and 1.23 (95% CI: 1.12–1.35) in women; for all-cause
mortality, the HRs were 1.13 (95% CI: 1.09–1.18) and 1.17 (95% CI: 1.10–1.25), respectively. The results were similar
across countries.
Conclusions: Depressive symptoms predicted CVD and all-cause mortality independently of a wide range of potential
confounders. The association followed a gradient and increased mortality risks were associated with scores below the
cut-offs that are commonly used to define ‘depression’.
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Numerous studies have shown that depression increases
the risk of cardiovascular disease (CVD), largely inde-
pendently of other risk factors.1–3 Several mechanisms
are suggested to explain this association, including
health behaviours (e.g. smoking, physical inactivity or
alcohol consumption) and direct effects (e.g. via
increased platelet activity, inFammation, alterations in
the hypothalamic–pituitary–adrenal axis or increased
activity of the sympathetic nervous system).4–8
However, the causal role of depression remains debated
because the observational evidence is not entirely con-
sistent9 and because experimental studies of the effects
of depression treatment on cardiovascular outcomes
produced ambiguous results.10–13 Another question
relates to whether mortality is associated only with
severe depression or whether it is also predicted by
milder symptoms of psychological distress.14
As long as studies of the relationship between depres-
sion and CVD adopt observational designs, there will be
problems of potential confounding. One way to address
this issue is to conduct studies in different settings.
In different social contexts, the correlation between
depression, confounding factors and CVD may follow
different patterns; this may help establish whether the
observational associations are due to confounding. In
Central and Eastern Europe, the structure and correl-
ation of potential confounders differ from Western
countries, where the vast majority of previous observa-
tional studies have been based. In addition, Central and
Eastern European countries have undergone rapid and
radical political, economic and social changes. It is not
implausible that these changes affected mental well-
being, and it has been estimated that the burden of ill
health attributable to major depression was five-times
higher in Eastern Europe than in Western Europe.15
Confirmation of this association in different social con-
texts provides the evidence that is necessary to assess
whether the observed association is causal and whether
psychological distress or depression can be regarded as
cardiovascular risk factors.
The objective of the present study was to investigate
the association between depressive symptoms and all-
cause and CVD mortality in populations of Central and
Eastern Europe and to assess whether the association
between depressive symptoms and CVD is graded and
is present across the full range of depressive symptoms
severity.
Methods
Study population and subjects
The Health, Alcohol and Psychosocial factors In
Eastern Europe (HAPIEE) project recruited random
population samples in Krakow (Poland), Novosibirsk
(Russia) and six Czech towns (Havirov-Karvina,
Hradec Kralove, Jihlava, Kromeriz, Liberec and Usti
nad Labem). Comprehensive information on the meth-
odology of the HAPIEE project was previously
described.16 A summary of information that is import-
ant for this paper is given below.
The baseline examination was conducted between
2002 and 2005 in a total number of 28,945 men and
women aged 45–69 years (overall participation rate:
59%).16 All participants gave written consent.
Questionnaires
At baseline, participants were interviewed by trained
nurses using a standardized questionnaire. In the
HAPIEE project, all questionnaires were translated
from English into each language and back translated
into English to check for accuracy. Information on
depressive symptoms, age, education, marital status,
employment, health status (history of CVD, cancer,
hypertension, diabetes or hypercholesterolaemia) and
health behaviours (smoking, physical activity and alco-
hol intake) was obtained.
Depressive symptoms were assessed using the Center
for Epidemiologic Studies Depression (CES-D) scale.17
This consisted of 20 self-reported items referring to
symptoms occurring during the past week. The severity
of each item was scored 0, 1, 2 or 3; thus, the total score
range was 0–60. Calculation of the final score allowed
for a maximum of four missing answers; in those who
gave between 16 and 19 responses, the average score
from the answers was calculated, divided by the
number of questions answered and multiplied by 20.
The CES-D scale was previously validated in all three
countries.18–20 In the analysis, the depression score was
used as (1) a continuous variable and (2) a variable with
four categories: free of depression symptoms (0–10),
low (11–15), mild (16–19) and moderate/severe depres-
sive symptoms (20–60). The original CES-D tool sug-
gested that a score 16 had good sensitivity and
specificity21; the remaining cut-offs were adopted arbi-
trarily in order to ensure sufficient numbers of subjects
per category.
Physical activity was assessed by a question about
duration of leisure time and sport-related physical
activity in a typical week. Current smoking status was
assigned for persons smoking cigarettes regularly or
occasionally. Ex-smokers were those who had smoked
in the past but stopped. Persons who had never smoked
cigarettes were considered to be non-smokers. Alcohol
intake was assessed using the Graduated Frequency
Questionnaire.22 History of doctor-diagnosed CVD
and cancer with and without hospitalisation were
coded as dichotomous variables.
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Physical examination
Height and weight were measured in the vertical pos-
ition using scales with a built-in ruler, with participants
wearing light indoor clothing and no shoes. Body mass
index (BMI) was calculated in terms of kg/m2. Blood
pressure was measured after at least a 5-minute rest, in
a sitting position, on the right arm, three times at two-
minute intervals using an Omron M5-I digital blood
pressure monitor. The average of the last two measure-
ments was used in the analysis. Hypertension was
defined as blood pressure 140/90mmHg or receiving
antihypertensive treatment in the 2 weeks prior to
examination.
Blood tests
Venous blood was collected using vacuum tubes from
participants after overnight fasting. Blood was stored at
þ4C and centrifuged within 4 hours of the venepunc-
ture. In Poland, the analyses were carried out on the
same day; in the Czech Republic and Russia, serum
samples were frozen and stored at –20C until the ana-
lysis. In all centres, blood lipids were determined by the
automated enzymatic colorimetric method23 using
reagents from Boehringer Mannheim Diagnostics and
Hoffmann-La Roche. Low-density lipoprotein choles-
terol was calculated by the Friedewald formula.
Hypercholesterolaemia was defined as total choles-
terol 5mmol/L, low-density lipoprotein cholesterol
3mmol/L or receiving lipid-lowering treatment.
Glucose concentration in plasma was assessed using
the enzymatic method. Diabetes was defined as
having fasting plasma glucose 7mmol/L or having
diabetes diagnosed by a doctor.
Registration of deaths
The cohorts were followed up for cause-specific mortal-
ity until 31 December 2010 in Poland and Russia and
until 31 December 2011 in the Czech Republic. In
Russia, information on deaths was obtained from the
death register developed by the Institute of Internal
Medicine, based on data from medical death certificates,
the Novosibirsk office of the State Statistical Bureau
(Goscomstat) and from the population registration
bureau. In Poland, data from the Local Register of
Residents of the City of Krakow and Central
Statistical Office were used. In the Czech Republic,
data from the National Death Register were used.
Cardiovascular deaths were those with International
Statistical Classification of Diseases and Related
Health Problems (10th edition) (ICD-10) codes I.00–
I.99. The mortality register in Novosibirsk was set up
for the World Health Organization MONItoring trends
and determinants in CArdiovascular disease (MONICA)
project24 and has been in operation since then; it is
believed to provide complete coverage of deaths in the
study population.25,26 Both Poland and the Czech
Republic are countries with nearly 100% completeness
of the registration of death and good accuracy of certifi-
cation of the causes of deaths for the broad category ‘dis-
eases of the circulatory system’ (ICD-10: I.00–I.99).27,28
Statistical analyses
Participants who agreed to follow-up and had non-
missing data on CES-D were included in the analyses.
A total of 2,452 Russian participants who were inter-
viewed by nurses and whose data failed quality control
for CES-D were excluded from the analysis.29 The dis-
tributions of CES-D scores and other variables in men
and women were examined in each country and in the
whole study sample. The relationships between CES-D
score and all-cause and CVD mortality were assessed
using the Cox proportional hazards model with two
levels of adjustment: (1) adjustment for age (continu-
ous); and (2) adjustment for age, education (categor-
ical), marital status (binary), occupational status
(binary), history of CVD (binary), smoking, (categor-
ical), BMI (continuous), hypercholesterolaemia
(binary), hypertension (binary), alcohol intake (con-
tinuous), physical activity (continuous) and history of
cancer (binary) in analyses of all-cause mortality.
Proportional hazard assumptions were checked using
Schoenfeld residuals. The timescale used was the time
since assessment of exposure (alternative use of age as a
timescale produced virtually identical results). Because
of the two-stage nature of the examination, the partici-
pation rate for the clinical examination was lower than
for the interview. Thus, the number of persons included
in the multivariate models was lower (by approximately
16%), as the sample was restricted to participants with-
out missing data on any of the covariates (9575 men
and 10,920 women). Interactions between depression
symptoms and country, sex and other variables were
assessed using likelihood ratio tests. Since there were
no significant interactions (all p-values >0.1), the data
from the three countries were pooled. Models were
fitted with CES-D score, used as both a continuous
and a categorical variable. In the pooled sample,
using all three countries together, clustered analysis
with robust standard errors was performed. All statis-
tical analyses were conducted using Stata version 12.1
(StataCorp LP, TX, USA).
Results
There were 13,617 men and 15,328 women examined at
baseline (response rate: 59%). Out of these, 11,528 men
and 13,014 women agreed to follow-up and had
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non-missing data on CES-D. In total, there were 80,517
and 94,316 person-years of observation in men and
women, respectively; among these, 2091 participants
died during the follow-up, and CVD was the most
common cause of deaths both in men (41%) and
women (39%) (Table 1).
The distribution of the baseline CES-D score was
highly right-skewed in all countries. A higher propor-
tion of men than women were free of depressive symp-
toms (63% vs. 48%) (Supplementary Figure 1).
The mean age at baseline was 58.2 years (SD¼ 7.0)
in men and 57.7 years (SD¼ 7.1) in women
(Supplementary Tables 1 and 2). A high percentage of
participants had secondary education. In all countries,
more men than women were married or cohabiting and
professionally active. Smoking patterns in men and
women were similar in Poland and in the Czech
Republic, while in Russia, the proportion of smokers
was very high in men and very low in women. In all
cohorts, alcohol consumption was higher in men.
Hypertension and diabetes were more prevalent in
men, while hypercholesterolaemia was more frequent
in women. A positive history of CVD was reported
by 21% of men and 18% of women.
The associations between depressive symptoms and
CVD mortality are shown in Table 2. After adjustment
for age, the risk of CVD mortality in the highest cat-
egory of CES-D score was approximately double that
of the lowest category. Pooled analysis of all three
countries confirmed a graded increase in CVD mortal-
ity by depressive symptoms in both sexes. Further
adjustment for education, occupational status, smok-
ing, BMI, hypercholesterolaemia, hypertension, alcohol
intake and history of CVD attenuated the relationship
by approximately 40%. Nevertheless, the graded asso-
ciations remained significant; in analyses of the con-
tinuous CES-D score, the adjusted hazard ratio (HR)
for a 1-SD increase in score was 1.20 (95% confidence
interval (CI): 1.16–1.24) in men and 1.23 (95% CI:
1.12–1.35) in women.
The associations of depressive symptoms with all-
cause mortality (Table 3) were somewhat weaker than
with CVD deaths. In the pooled analysis of the three
cohorts, the age-adjusted HRs of death in men and
women with CES-D scores of >20 versus 10 were
1.94 (95% CI: 1.77–2.13) and 2.14 (95% CI:
1.75–2.61), respectively. Multivariable adjustment
reduced the HRs to a greater extent than in analyses
Table 1. Sample size and number of deaths by country and sex.
Czech Republic Russia Poland Total




4123 4264 5230 13,617
Follow-up 3955 95.9 4190 98.3 4872 93.2 13,017 95.6
Follow-up
þCES-D
3707 89.9 3046 71.4 4775 91.3 11,528 84.7
Person-years 29,193 18,433 32,892 80,517
Number
of deaths
431 11.6 431 14.3 528 11.1 1390 12.1
Number of
CVD deaths




4734 5096 5498 15,328
Follow-up 4517 95.4 5028 98.7 5140 93.5 14,685 95.8
Follow-up
þCES-D
4230 89.4 3748 73.5 5036 91.6 13,014 84.9
Person-years 34,254 24,324 35,739 94,316
Number
of deaths
232 5.5 185 5.0 284 5.6 701 5.4
Number of
CVD deaths
76 1.8 102 2.7 96 1.9 274 2.1
CES-D: Center for Epidemiologic Studies Depression; CVD: cardiovascular disease.
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of CVD mortality, but in both sexes, the associations of
the continuous CES-D score with all-cause mortality
remained statistically significant.
Additional sensitivity analyses supported these
results. First, exclusion of deaths in first 2 years of
follow-up did not change the findings (Supplementary
Table 3). Second, the results were unchanged after
exclusion of participants who reported existing CVD
at baseline (Supplementary Tables 4 and 5). Third, as
the covariates in the final model are a mix of potential
confounders and mediators, we have estimated models
separately adjusted for age plus socioeconomic vari-
ables (unlikely to be mediators) and additionally
adjusted for potential mediators (e.g. alcohol, smoking
and hypertension); there was some attenuation of HRs
after adding potential mediators (Supplementary
Tables 4 and 5). Finally, the association with non-
CVD deaths was weaker than with CVD deaths, con-
firming a relative specificity of the association with
CVD; for example, the fully adjusted HRs for men
and women with CES-D scores of >20 versus 10 in
the combined dataset were 1.94 (95% CI: 1.64–2.29)
and 2.1 (95% CI: 1.73–2.55), respectively (data not
shown).
Discussion
This large prospective cohort study found significant
positive associations between increasing depressive
symptoms and CVD mortality and, to a lesser extent,
with all-cause mortality. Although the age-adjusted
associations were attenuated after multivariable adjust-
ment, a graded relationship between CES-D score and
mortality remained significant. To the best of our
Table 2. Association between Center for Epidemiologic Studies Depression scores and risk of cardiovascular disease death by sex.
Czech Republic Russia Poland
All three countries
(cluster) p-value for
CES-D score HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) interaction
Men
Age-adjusted 0–10 1.00 1.00 1.00 1.00
11–15 1.30 (0.89–1.89) 1.30 (0.94–1.80) 1.38 (0.93–2.03) 1.32 (1.28-1.36)
16–20 1.24 (0.68–2.26) 1.91 (1.26–2.88) 2.13 (1.39–3.27) 1.78 (1.52–2.08) 0.805
21þ 2.34 (1.43–3.83) 2.14 (1.43–3.22) 2.72 (1.83–4.03) 2.36 (2.09–2.66)
p-value for trend 0.002 <0.001 <0.001 <0.001
1 SD increase 1.30 (1.14–1.47) 1.29 (1.16–1.44) 1.43 (1.27–1.61) 1.35 (0–1.31) 0.574
Fully adjusteda 0–10 1.00 1.00 1.00 1.00
11–15 0.85 (0.52–1.39) 1.21 (0.87–1.69) 1.00 (0.62–1.61) 1.03 (0.86–1.23)
16–20 1.17 (0.59–2.31) 1.63 (1.07–2.48) 1.31 (0.76–2.27) 1.37 (1.23–1.54) 0.949
21þ 1.82 (0.98–3.36) 1.63 (1.07–2.49) 1.76 (1.07–2.88) 1.68 (1.62–1.74)
p-value for trend 0.130 0.005 0.033 <0.001
1 SD increase 1.18 (1.00–1.40) 1.19 (1.06–1.34) 1.2 (1.01–1.42) 1.20 (1.16–1.24) 0.972
Women
Age-adjusted 0–10 1.00 1.00 1.00 1.00
11–15 1.72 (0.98–3.03) 1.37 (0.81–2.34) 1.54 (0.90–2.63) 1.57 (1.43–1.74)
16–20 1.58 (0.75–3.36) 1.51 (0.85–2.68) 1.67 (0.93–2.97) 1.71 (1.63–1.79) 0.992
21þ 2.46 (1.36–4.45) 1.87 (1.12–3.12) 1.86 (1.09–3.18) 2.16 (1.86–2.52)
p-value for trend 0.003 0.015 0.016 <0.001
1 SD increase 1.41 (1.18–1.69) 1.22 (1.02–1.45) 1.32 (1.10–1.58) 1.35 (1.27–1.43) 0.582
Fully adjusteda 0–10 1.00 1.00 1.00 1.00
11–15 2.30 (1.01–5.27) 1.30 (0.76–2.22) 1.34 (0.65–2.73) 1.60 (1.24–2.06)
16–20 2.89 (1.10–7.62) 1.32 (0.74–2.34) 2.19 (1.12–4.30) 2.06 (1.4–3.04) 0.608
21þ 2.15 (0.84–5.47) 1.24 (0.73–2.10) 1.45 (0.68–3.09) 1.77 (1.49–2.11)
p-value for trend 0.059 0.460 0.150 0.012
1 SD increase 1.37 (1.06–1.77) 1.04 (0.86–1.25) 1.18 (0.92–1.52) 1.23 (1.12–1.35) 0.215
aAdjusted for age, education, marital status, occupational status, history of cardiovascular disease, smoking, body mass index, hypercholesterolaemia,
hypertension, physical activity and alcohol intake.
CI: confidence interval; CES-D: Center for Epidemiologic Studies Depression; HR: hazard ratio.
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knowledge, this is by far the largest prospective cohort
study using standard methods in the general population
in Central and Eastern Europe.
Several limitations of the study need to be considered.
First, the participation rate of 59% may have affected
the representativeness of the study sample. Response
rates in epidemiological studies have been declining
over recent decades, and lower response rates may
affect the estimates of disease rates. The analysis of the
Polish cohort, in which data on the mortality of both
respondents and non-respondents were available,
showed that non-respondents had higher mortality and
a greater prevalence of CVD risk factors than study par-
ticipants.30 However, empirical data suggest that
response rates do not necessarily influence the estimates
of the examined associations substantially.31,32 At least
in Poland, the cohort has been shown to be similar to the
general urban population of that country with respect to
marital status, occupational status, smoking, BMI,
prevalence of hypercholesterolaemia, hypertension and
hyperglycaemia and the Systematic COronary Risk
Evaluation (SCORE) risk category.33 In addition, par-
ticipants who did not attend the physical examination
had a higher mortality risk than those who did attend
the physical examination. Therefore, our results are
based on the healthier part of the cohort,30 and this
might have resulted in some underestimation of the asso-
ciations between depression and mortality.
Second, while the CES-D scale is a widely accepted
tool that has been validated in many countries, includ-
ing those represented in our study, the possibility that
the scale’s performance is not completely identical in all
populations cannot be excluded. In addition, depressive
symptoms were only assessed once (at baseline) and we
Table 3. Association between Center for Epidemiologic Studies Depression scores and risk of death from all causes by sex.
Czech Republic Russia Poland
All three countries
(cluster) p-value for
CES-D score HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) interaction
Men
Age-adjusted 0–10 1.00 1.00 1.00 1.00 0.987
11–15 1.37 (1.09–1.72) 1.42 (1.13–1.79) 1.31 (1.05–1.63) 1.36 (1.31–1.41)
16–20 1.79 (1.3–2.46) 1.66 (1.21–2.28) 1.82 (1.41–2.35) 1.76 (1.64–1.88)
21þ 2.07 (1.5–2.85) 1.84 (1.34–2.52) 1.98 (1.54–2.55) 1.94 (1.77–2.13)
p-value for trend <0.001 <0.001 <0.001 <0.001
1 SD increase 1.26 (1.17–1.37) 1.21 (1.12–1.31) 1.30 (1.21–1.41) 1.27 (1.24–1.29) 0.785
Fully adjusteda 0–10 1.00 1.00 1.00 1.00
11–15 1.10 (0.82–1.47) 1.29 (1.02–1.63) 1.10 (0.84–1.44) 1.14 (1.03–1.26)
16–20 1.59 (1.07–2.37) 1.44 (1.04–1.99) 1.31 (0.95–1.81) 1.38 (1.22–1.55) 0.773
21þ 1.76 (1.16–2.66) 1.36 (0.97–1.89) 1.31 (0.95–1.8) 1.41 (1.2–1.64)
p-value for trend 0.002 0.009 0.047 <0.001
1 SD increase 1.18 (1.06–1.31) 1.10 (1.01–1.21) 1.12 (1.01–1.24) 1.13 (1.09–1.18) 0.546
Women
Age-adjusted 0–10 1.00 1.00 1.00 1.00
11–15 1.59 (1.14–2.21) 1.40 (0.95–2.06) 1.44 (1.05–1.98) 1.49 (1.39–1.6)
16–20 1.64 (1.07–2.51) 1.62 (1.07–2.45) 1.49 (1.05–2.12) 1.63 (1.5–1.76) 0.662
21þ 2.54 (1.82–3.54) 1.58 (1.06–2.34) 2.12 (1.58–2.86) 2.14 (1.75–2.61)
p-value for trend <0.001 0.017 <0.001 <0.001
1 SD increase 1.41 (1.27–1.56) 1.19 (1.04–1.35) 1.34 (1.2–1.48) 1.35 (1.25–1.42) 0.189
Fully adjusteda 0–10 1.00 1.00 1.00 1.00
11–15 1.28 (0.83–2.00) 1.35 (0.92–1.99) 1.15 (0.79–1.68) 1.30 (1.18–1.44)
16–20 1.56 (0.90–2.71) 1.49 (0.99–2.26) 1.18 (0.78–1.79) 1.46 (1.23–1.73) 0.909
21þ 1.61 (1.01–2.6) 1.27 (0.85–1.90) 1.27 (0.86–1.88) 1.47 (1.3–1.65)
p-value for trend 0.030 0.230 0.210 0.005
1 SD increase 1.26 (1.09–1.47) 1.09 (0.95–1.24) 1.10 (0.96–1.26) 1.17 (1.10–1.25) 0.289
aAdjusted for age, education, marital status, occupational status, history of cardiovascular disease, history of cancer, smoking, body mass index,
hypercholesterolaemia, hypertension, physical activity and alcohol intake.
CI: confidence interval; CES-D: Center for Epidemiologic Studies Depression; HR: hazard ratio.
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were not able to consider the course of depression. One
would expect that that these issues would underesti-
mate the associations with mortality.
Third, a major issue in observational studies of
depression and mortality is the independence of the
observed association. Depression and distress are asso-
ciated with numerous factors (e.g. socioeconomic status
and health behaviours), which may confound or medi-
ate the association.34 Although we adjusted for a large
number of such factors, it cannot be certain whether the
remaining effect is due to depressive symptoms alone or
whether it is due to residual confounding. The substan-
tial reduction of HRs after adjustment may indicate the
presence of residual confounding due to unmeasured
factors; on the other hand, the multivariable model
may also have led to an over-adjustment, since some
of the variables included in the final model may be
mediators, rather than confounders, or both confoun-
ders and mediators (e.g. alcohol). The (relatively
modest) attenuation of HRs after the inclusion of
potential mediators suggests that the full models may
lead to an underestimation of the real effect.
Our findings were generally consistent across the
sexes and cohorts. Additional analysis showed no sub-
stantial changes in the results after excluding partici-
pants with a history of CVD or excluding deaths
within the first 2 years of observation; this argues against
a major reverse causation bias. Importantly, our results
are consistent with most previous studies, confirming
depression as a predictor (whether as a causal factor or
not) of all-cause and CVD mortality.2,35,36 Although the
possibility of false-positive findings cannot be excluded,
the presence of a graded association, including less
severe symptoms, further supports the existence of a
genuine association between depression symptoms and
mortality.
The causality of this association remains unclear,
although there are several psychobiological mechan-
isms that may plausibly link depression with somatic
disorders such as CVD. Depression contributes to
hypothalamic–pituitary–adrenal axis hyperactivity.
Findings from other studies show that depressed per-
sons are more likely to have increased cortisol and
adrenocorticotropic hormone levels, with no effect on
corticotropin-releasing hormone.37 Dysfunction of the
autonomic nervous system may also link depression
with CVD, as depression is associated with reduced
heart rate variability, which decreases with increasing
depression severity.38 Furthermore, depressed persons
were reported to have higher concentrations of inflam-
matory biomarkers compared to healthy subjects, and
inflammation is an established accelerator of athero-
sclerosis.39–41 Inflammatory responses may be caused
by alterations in the autonomic system and in the hypo-
thalamic–pituitary–adrenal axis.42,43
On the other hand, intervention studies found that
treatment of depression – either pharmacological or
behavioural – was associated with modest improve-
ments in depressive symptoms, but were inconclusive
in terms of improvements in cardiac outcomes.
However, these studies were conducted on patients
with existing CVD, and there is no relevant evidence
from general population samples.10,12,13 The relation-
ship between depression and cardiac outcome could
also be confounded by the association between the
use of some antidepressants and a higher prevalence
of ischaemic heart disease.44,45
Whether causal or not, there is solid evidence that
depression remains a strong predictor of CVD mortal-
ity, with the strength of the association being compar-
able to classic CVD risk factors. Our study reports the
presence of this association in the context of popula-
tions undergoing radical societal transformation.46 The
graded association with symptom severity suggests that
the conventional cut-offs for the CES-D scale do not
adequately identify persons who are at increased risk of
CVD death.
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Umieralność na Choroby Ukiadu Kraz_enia a Sytuacja
Demograficzna Polski. Warszawa: Rzadowa Rada
Ludnościowa, 2015.
28. WHO Regional Office for Europe. Measurement and
Targets. Final Report of the Task Group on
Measurement and Targets. Review of Social
Determinants of Health and the Health Divide in the
WHO European Region. Copenhagen: WHO Press, 2016.
29. Nicholson A, Pikhart H, Pajak A, et al. Socio-economic
status over the life-course and depressive symptoms in
men and women in Eastern Europe. J Affect Disord
2008; 105(1–3): 125–136.
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